As Celltrion Healthcare announces the launch of the biobetter version of Remsima (Remsima SC) in Brazil, the company shared the phase 3 plan for its ocrelizumab biosimilar to treat multiple sclerosis (MS).
Celltrion Healthcare shared 2 announcements, including the Brazilian launch of Remisma SC, a biobetter of the company’s infliximab biosimilar (Remsima) that allows for subcutaneous administration, and a phase 3 plan for an ocrelizumab biosimilar.
Brazilian Launch of Remsima SC
Celltrion launched Remsima SC in Brazil, the largest pharmaceutical market in South America, as reported by the Korea Herald.
Remsima SC is the only infliximab product in the world that allows for subcutaneous administration and is unique as a biobetter in that it is an improvement to a biosimilar rather than an originator product. Biobetters are a class of follow-on biologic products that are intentionally altered to improve clinical effects, allow for more time in between doses, or enhance tolerability. Subcutaneous administration can allow for more convenient administration compared with intravenous administration.
The biobetter is indicated for inflammatory bowel disease, which is an umbrella term for Crohn disease and ulcerative colitis. Remsima SC was approved by the Brazilian Health Regulatory Agency in November 2022.
Celltrion will be responsible for direct sales of Remsima SC in Brazil, and the company said that it increased the number of staff members at its Brazil office to improve marketing capabilities for the biobetter. The original Remsima and Truxima, Celltrion’s rituximab biosimilar, have secured 84% and 70% market share in their respective markets in Brazil.
Celltrion said that it plans to increase sales of Remsima SC in Brazil before expanding in other countries because Brazil accounts for than half of the South American pharmaceutical market. The company predicted that many existing patients taking Remsima will switch to Remsima SC.
“(Celltrion Healthcare) plans to introduce Remsima SC in Mexico, Colombia and Peru first during the second half this year, where the company has regional offices,” said a Celltrion Healthcare official.
Phase 3 Plan for MS Biosimilar
In addition, Celltrion said that it submitted a phase 3 investigational new drug (IND) plan to the FDA for CT-P53, an ocrelizumab candidate referencing Ocrevus that would be used to treat multiple sclerosis (MS), according to a report from Korea Biomedical Review.
The phase 3 clinical trial will include 512 patients from around the world with recurrent palliative multiple sclerosis and will assess the effectiveness, pharmacokinetics, and safety between the biosimilars and the reference product.
Ocrevus is an autoimmune disease treatment developed by Roche that is used to teat recurrent MS and primary progressive MS. As of 2022, the originator has maintained its status as the top selling MS treatment, with sales reaching about $6.8 billion, $5.1 billion of which is attributed to the US market alone. The US market represents over 70% of the total ocrelizumab market.
“We plan to accelerate the development of the product based on the unique experience and know-how accumulated in the field of autoimmune diseases by submitting the IND of CT-P53 to global regulators,” a Celltrion representative commented.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars Gastroenterology Roundup for May 2024—Podcast Edition
June 2nd 2024On this episode of Not So Different, we review the biggest gastroenterology biosimilar stories from May 2024, covering new data from conferences and journals on infliximab and adalimumab products that demonstrate positive clinical results and confirm the safety of these biosimilars, as well as the feasibility of switching to them.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.
2 Commerce Drive
Cranbury, NJ 08512